Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

3-TYP

Catalog No. T4108Cas No. 120241-79-4
Alias 3-(1H-1,2,3-triazol-4-yl) pyridine

3-TYP (3-(1H-1,2,3-triazol-4-yl) pyridine) is a selective SIRT3 inhibitor.

3-TYP

3-TYP

Purity: 100.00%
Catalog No. T4108Alias 3-(1H-1,2,3-triazol-4-yl) pyridineCas No. 120241-79-4
3-TYP (3-(1H-1,2,3-triazol-4-yl) pyridine) is a selective SIRT3 inhibitor.
Pack SizePriceAvailabilityQuantity
5 mg$52In Stock
10 mg$89In Stock
25 mg$178In Stock
50 mg$275In Stock
100 mg$495In Stock
500 mg$1,120In Stock
1 mL x 10 mM (in DMSO)$52In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "3-TYP"

Select Batch
Purity:100.00%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
3-TYP (3-(1H-1,2,3-triazol-4-yl) pyridine) is a selective SIRT3 inhibitor.
Targets&IC50
SIRT1:88 nM, SIRT3:16 nM, SIRT2:92 nM
In vitro
3-TYP significantly attenuates melatonin-induced increases in deacetylated-SOD2 expression and SOD2 activity in HepG2 cells exposed to Cd. 3-TYP inhibits melatonin-enhanced SIRT3 activity while not affecting SIRT3 protein expression. 3-TYP pretreatment reverses the protective effects of melatonin on cadmium (Cd)-induced mitochondrial-derived O2•− production and autophagic cell death.
In vivo
3-TYP significantly reduces SIRT3 activity and increases SOD2 acetylation compared to the control group while not affecting SIRT3 expression. It undermines the cardioprotective effects of melatonin by reducing left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) and increases infarct size, serum lactate dehydrogenase (LDH) levels, and the apoptotic ratio after 24 hours of reperfusion, relative to the IR+Mel group. However, at a dose of 50 mg/kg, intraperitoneally (i.p.), 3-TYP shows no significant effect on LVEF, LVFS, infarct size, serum LDH levels, apoptosis, and oxidative stress compared to the Sham group. Additionally, 3-TYP does not significantly affect the expression levels of gp91phox, Nrf2, NQO 1, Bax, Bcl-2, Caspase-3, and cleaved Caspase-3 compared to the Sham group.
Cell Research
Cell viability is analyzed using Cell Counting Kit-8. 1×104 cells are inoculated into 96-well plates. After being treated, 90 μL of medium and 10 μL of CCK-8 solution are added to each well. The cells are then incubated at 37°C for 2 h. After incubation, the absorption at 450 nm is measured using an Infinite? M200 Microplate Reader. The results are expressed as a percentage of the control. The cell death is also evaluated using the trypan blue assay. HepG2 cells are plated in the 6-well plates (5×105 cells per well) and incubated for 24 h. After being treated with Cd or melatonin, the cells are detached with 300 μL trypsin-EDTA solution. The mixture of detached cells is centrifugated at 300 g for 5 min. Then, the residue is combined with 800 μL trypan blue solution and dispersed. After 3 min staining, cells are counted using an automated cell counter. The dead cells are stained with the blue color. Cell mortality (%) is expressed as percentage of the dead cell number/the total cell number.
Animal Research
3-TYP is formulated in 1% ethanol.Male C57BL/6 mice are anesthetized with 2% isoflurane, and myocardial ischemia is produced by temporarily exteriorizing the heart via a left thoracic incision and placing a 6-0 silk suture slipknot around the left anterior descending coronary artery. After 30 minutes of myocardial ischemia, the slipknot is released, and the myocardium is reperfused for 3 hour (for western blot analysis and oxidative stress measurement) or 24 hour (for cardiac function, apoptotic index and infarct size determination). Sham-operated mice undergo the same surgical procedures except the suture placed under the left coronary artery is not tied. Ten minutes before reperfusion, mice are randomized to receive either vehicle (1% ethanol) or melatonin (20 mg/kg) by intraperitoneal injection. C57BL/6 mice are randomly divided into the following groups: (i) Sham group: mice underwent the sham operation and are treated with vehicle (1% ethanol); (ii) Mel group: mice are treated with melatonin (20 mg/kg via intraperitoneal injection); (iii) IR+V group: mice underwent the MI/R operation and are treated with vehicle (1% ethanol); (iv) IR+Mel group: mice underwent the MI/R operation and are treated with melatonin (20 mg/kg via intraperitoneal injection 10 minutes before reperfusion); (v) IR+Mel+3-TYP group: mice are pretreated with 3-TYP (3-TYP is intraperitoneally injected at a dose of 50 mg/kg every 2 days for a total of three doses prior to the MI/R surgery), subjected to the MI/R operation, and treated with melatonin (20 mg/kg via intraperitoneal injection 10 minutes before reperfusion); and (vi) IR+3-TYP group: mice are pretreated with 3-TYP and then subjected to the MI/R operation.
Alias3-(1H-1,2,3-triazol-4-yl) pyridine
Chemical Properties
Molecular Weight146.15
FormulaC7H6N4
Cas No.120241-79-4
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
H2O: 5 mg/mL (34.21 mM)
Ethanol: 28 mg/mL (191.6 mM)
DMSO: 65 mg/mL (444.75 mM)
Solution Preparation Table
H2O/Ethanol/DMSO
1mg5mg10mg50mg
1 mM6.8423 mL34.2114 mL68.4229 mL342.1143 mL
5 mM1.3685 mL6.8423 mL13.6846 mL68.4229 mL
10 mM0.6842 mL3.4211 mL6.8423 mL34.2114 mL
20 mM0.3421 mL1.7106 mL3.4211 mL17.1057 mL
Ethanol/DMSO
1mg5mg10mg50mg
50 mM0.1368 mL0.6842 mL1.3685 mL6.8423 mL
100 mM0.0684 mL0.3421 mL0.6842 mL3.4211 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy 3-TYP | purchase 3-TYP | 3-TYP cost | order 3-TYP | 3-TYP chemical structure | 3-TYP in vivo | 3-TYP in vitro | 3-TYP formula | 3-TYP molecular weight